Recordati — Merger or Acquisition (December 2021)

5 slides from Recordati's merger presentation, Dec 3, 2021

Slide 1: Acquisition
Acquisition Milano, 3 December 2021
Slide 2: Strategic rationale of the transaction
Strategic rationale of the transaction Further development and expansion of our Rare Diseases portfolio ✓ Further strengthens the growth of our rare disease franchise, in line with our 3-year strategy, building on top of the current solid organic growth of the division ✓ Broadens Recordati’s rare di
Slide 3: EUSA Pharma
EUSA Pharma Transformative assets with global growth potential, offering platform for further expansion Company highlights Overview Regional Revenue breakdown 2021 LTM (1) • EUSA Pharma (UK), founded in 2015, is a world-class specialty pharmaceutical company 13% • High growth portfolio of 4 in-marke
Slide 4: Financial snapshot
Financial snapshot • Expected over €150 million of revenue by 2023 and annual peak sales of ~€250 million Key business • EBITDA(1) ~€50 million in 2023 with long term margin in line with average of Rare Disease segment financials • Non-recurring costs in 2022-2023 from on-going manufacturing technol
Slide 5: Company declarations, disclaimers and profile
Company declarations, disclaimers and profile DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY’S FINANCIAL REPORTS The manager responsible for preparing the company’s financial reports Luigi La Corte declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Fina